A LAT1-Compatible, Leadlike Tyrosine-Naphthoquinone Conjugate With Anticancer Activity.

Area of Science:

• Medicinal Chemistry
• Molecular Pharmacology
• Cancer Therapeutics

Background:

• L-type amino acid transporter 1 (LAT1) is overexpressed in various cancers.
• Targeting LAT1 offers a strategy for selective cancer therapy.
• Naphthoquinone (NQ) derivatives possess anticancer properties.

Purpose of the Study:

• To develop a LAT1-compatible, anticancer-active tyrosine-NQ conjugate.
• To evaluate the selective cytotoxicity of the conjugate towards cancer cells.
• To investigate the mechanism of action and drug-like properties of the conjugate.

Main Methods:

• Synthesis and characterization of the tyrosine-NQ conjugate.
• Cell viability assays (IC50, competition studies) using cancer (PC3) and non-cancerous (HEK293) cells.
• Molecular docking studies to assess LAT1 compatibility.
• In silico pharmacological profiling and structure-activity relationship (SAR) assessment.
• Cell imaging studies to observe cellular effects.

Main Results:

• The tyrosine-NQ conjugate demonstrated significant selective cytotoxicity against LAT1-overexpressing PC3 cells compared to HEK293 cells.
• Docking and competition studies confirmed LAT1 compatibility and facilitated uptake.
• SAR studies identified the aryloxy-naphthoquinone motif as crucial for anticancer activity.
• In silico studies indicated favorable lead-like properties for further drug development.
• Imaging revealed drug-induced stress responses in cancer cell nuclear morphology.

Conclusions:

• The developed tyrosine-NQ conjugate is a promising LAT1-targeting agent with selective anticancer activity.
• The conjugate represents a potential lead compound for developing novel naphthoquinone-based chemotherapeutics.
• Exploiting LAT1 overexpression is an effective strategy for targeted cancer drug delivery.